>>
<<
ISO 10993-7:2026(en)
ISO - Cover page
Foreword
Introduction
1 Scope
2 Normative references
3 Terms and definitions
4 Requirements
 4.1 General
 4.2 Categorization of devices
 4.3 Allowable limits
  4.3.1 General
  4.3.2 Limited exposure devices
  4.3.3 Prolonged exposure devices
  4.3.4 Long-term exposure devices
  4.3.5 Special situations
  4.3.6 Tolerable contact level
 4.4 Determination of EO and ECH residuals
  4.4.1 Procedure
  4.4.2 Test method validation
  4.4.3 Product sampling
  4.4.4 Sample/fluid ratios
  4.4.5 Product extraction
  4.4.6 Multi-device systems
5 Product release
 5.1 General
 5.2 Batch release of products
 5.3 Release of products at specified minimum aeration time
 5.4 Procedure for product release using residual dissipation curves
6 Adoption of products into established aeration family
7 Change evaluation
Annex A (informative) Guidance for the application of this document for the determination of EO and ECH residuals in medical devices
Annex B (informative) Factors influencing product residuals
Annex C (informative) Rationale for the provisions of this document
Annex D (informative) Establishment of allowable limits for EO
Annex E (informative) Establishment of allowable limits for ECH
Annex F (informative) Ethylene glycol
Annex G (normative) Evaluation of gas chromatograms
Annex H (informative) Gas chromatographic determination for EO and ECH
Annex I (informative) Preparation of EO and ECH standards
Annex J (informative) Ethylene oxide and ethylene chlorohydrin residual measuring methods
Annex K (informative) Examples of product release methods
Bibliography
30mm
20mm
15mm
15mm
10mm
17mm

International

Standard

ISO 10993-7
Biological evaluation of medical devices
Part 7:
Ethylene oxide sterilization residuals
Évaluation biologique des dispositifs médicaux —
Partie 7: Résidus de stérilisation à l'oxyde d'éthylène
Reference number
ISO 10993-7:2026(en)
Third edition
2026-04
30mm
20mm
15mm
15mm
10mm
17mm
30mm
20mm
15mm
15mm
10mm
17mm

ContentsPage

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.
The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).
ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.
Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.
For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.
This document was prepared by Technical Committee ISO/TC 194, Biological and clinical evaluation of medical devices, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, Biological and clinical evaluation of medical devices, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).
This third edition cancels and replaces the second edition (ISO 10993-7:2008), which has been technically revised. It also incorporates the Amendment ISO 10993-7:2008/Amd 1:2019 and the Technical Corrigendum ISO 10993-7:2008/Cor 1:2009.
The main changes are as follows:
—
allowable limits and extraction conditions have been derived based on the patient population and the duration of use;
—
the use of a risk assessment to establish allowable limits has been permitted;
—
additional guidance on product release has been provided;
—
additional guidance on determining residuals and the factors that affect residual has been provided.
A list of all parts in the ISO 10993 series can be found on the ISO website.
Any feedback or questions on this document should be directed to the user’s national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

As noted in the introduction to ISO 11135, when determining the suitability of ethylene oxide (EO) for sterilization of medical devices, it is important to ensure that the levels of residual EO and ethylene chlorohydrin (ECH) pose a minimal risk to the patient in intended product use. Therefore, it is important that the use of alternative materials and sterilization processes are considered during product design and development. EO is known to exhibit a number of biological effects. In the development of this document, consideration was given to these effects, which include irritation, organ damage, mutagenicity, carcinogenicity, and reproductive effects in humans and animals. Similar consideration was given to the harmful effects of ECH and ethylene glycol (EG). ECH can be formed when EO comes into contact with free chloride ions, whereas EG is a hydrolytic reaction product of EO and water. In practice, for most devices, exposure to EO and ECH is considerably lower than the maximum allowable limits established according to this document. No allowable limits are set for EG because risk assessment indicated that when EO residuals are controlled, it is unlikely that biologically significant residuals of EG would be present.
Requirements herein are in addition to the biological evaluation requirements as indicated in ISO 10993-1. The biological evaluation, combined with the EO-sterilization process residual limits, form the justification that an EO-sterilized device is safe for its anticipated contact duration. Maximum allowable residuals for ECH, when ECH has been found to be present in medical devices sterilized with EO, are also specified. Local effects (e.g. irritation) have been considered and are incorporated in the TCL as given in 4.3.6.2 and Annex D for EO, and in 4.3.6.3 and Annex E for ECH.
In this edition of this document (i.e. ISO 10993-7:2026), an uncertainty factor approach is used to derive EO and ECH exposure duration-specific tolerable intake (TI) values (expressed in µg/kg/d). Furthermore, this edition of this document (i.e. ISO 10993-7:2026) introduces the conversion of each EO and ECH TI value into subpopulation-specific cumulative exposure-allowable limit values (expressed in milligrams per device), which are used to determine the extent that EO and ECH, extracted under clinically relevant conditions and time-periods, needs to be reduced post-sterilization.
This edition of this document (i.e. ISO 10993-7:2026) applies a different approach as compared to ISO 10993-17:2023 to establishing allowable limits to make it useful for development, validation, and routine control of ethylene oxide sterilization in the manufacture of finished medical devices with focus on the risk assessments associated with three chemical constituents that are potentially left in medical devices sterilized with ethylene oxide. This document extends this knowledge further by calculating the largest amount of EO, ECH or EG that can be present in a medical device such that it would always meet the requirements of ISO 10993-17 when that device has been exposed to the validated sterilization cycle parameters. This maximum amount or allowable limit is expressed in milligrams per device deemed acceptable when taken into the body through exposure to that medical device. These allowable limits will help determine the appropriate sterilization parameters such as sterilant gas concentration and dwell, as well as aeration temperature and hold time when validating the sterilization process to be used for a product or group of products. Furthermore, the allowable limits can be used by regulatory bodies, manufacturers, and processors to optimize processes and aid in the selection and qualification of alternative materials in order to protect patient health.
30mm
20mm
15mm
15mm
10mm
17mm

International StandardISO 10993-7:2026(en)
Biological evaluation of medical devices
Part 7:
Ethylene oxide sterilization residuals

1Scope

This document specifies allowable limits (AL) for residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) in EO-sterilized medical devices, procedures for the measurement of EO and ECH, and methods for determining conformity so that devices can be released. Additional background, including guidance and a flowchart showing how this document is applied, are also included in Annexes A, B, C, D, E, F, G, H, I, J and K.
EO-sterilized devices or components that have neither direct nor indirect body or user contact (e.g. in vitro diagnostic devices) are out of scope of this document. This document does not apply to devices that have been demonstrated to not absorb or retain EO or its degradation product ECH, such as medical devices made exclusively of metal alloys and glass, see Clause C.5[228].
NOTEThis document does not specify limits for ethylene glycol (EG). No device limits are specified for EG because the risk assessment in Annex F indicates that calculated allowable levels are higher than those likely to occur in a medical device.

2Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.
ISO 10993-1:2025, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process
ISO 10993-23:2021, Biological evaluation of medical devices — Part 23: Tests for irritation

3Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 10993-1 and the following apply.
ISO and IEC maintain terminology databases for use in standardization at the following addresses:
—
ISO Online browsing platform: available at https://www.iso.org/obp
—
IEC Electropedia: available at https://www.electropedia.org/
3.1
aeration
part of the sterilization cycle (3.5) during which the sterilizing agent and/or its reaction products desorb from the health care product until predetermined levels are reached
Note 1 to entry: Aeration can be performed within the sterilization chamber or in a separate chamber or room.
[SOURCE: ISO 11139:2018, 3.7, modified — Note 1 to entry has been added.]
3.2
allowable limit
AL
amount of residual (3.19) ethylene oxide or ethylene chlorohydrin on a single device that is permitted as a condition of release for patient use
Note 1 to entry: Allowable limits are expressed in milligrams per device for each applicable exposure period. These limits represent acceptable biological risks for medical devices under the circumstances of their anticipated exposure duration.
3.3
cumulative exposure
total quantity of ethylene oxide and ethylene chlorohydrin that contacts the body for a specified period of time
Note 1 to entry: Cumulative exposure can apply when consecutive uses of the same device or of new devices of the same type for the same patient or user applies (e.g. when one device is used repeatedly over a specified period of time).
3.4
concomitant exposure factor
CEF
numerical safety (3.20) factor that accounts for patient exposure to the simultaneous use of other ethylene oxide sterilized medical devices different from the subject medical device
Note 1 to entry: CEF is calculated from the reciprocal of the number of devices (one divided by the number of devices) used during a procedure. The default value (3.6) of 0,2 assumes four other devices are used during a procedure, see 4.4.5 and Clause D.6 for further details.
3.5
cycle
set of sterilization process parameters
3.6
default value
value or factor used in the derivation of a tolerable contact level (3.22) or tolerable intake (3.24), in the absence of specific data [e.g. an uncertainty factor (3.26)]
[SOURCE: ISO 10993-17:2023, 3.5, modified — the "worst-case exposure dose" has been removed from the definition.]
3.7
dose-response
relationship of dosage to observable harm
Note 1 to entry: In general, there are two types of dose-response relationships. The first type is the change in response of an individual to a range of doses. The second type is the distribution of the response among individuals to a range of doses.
[SOURCE: ISO 10993-17:2023, 3.6]
3.8
exhaustive extraction
multi-step extraction conducted until the amount of material extracted in a subsequent extraction step is less than 10 % of that determined in the initial extraction step
Note 1 to entry: Based upon the boiling point of ethylene oxide (EO) (10,7 °C) and the knowledge that substances, other than EO and ethylene chlorohydrin, can be extracted from the device under evaluation, gravimetric analysis is not appropriate for determining the exhaustivity level.
[SOURCE: ISO 10993-18:2020, 3.15, modified — "by gravimetric analysis (or achieved by other means)" has been removed from the definition and Note 1 to entry has been added.]
3.9
harm to health
adverse reaction, such as altered morphology, physiology, growth, development, reproduction or lifespan that
a)
impairs function of an organ or system, organism or (sub)population,
b)
reduces capacity to tolerate an impaired function, or
c)
increases susceptibility to other influences that impair function
Note 1 to entry: Examples of (sub)population include, but are not limited to: male, female, preterm neonates, adults.
[SOURCE: ISO 10993-17:2023, 3.8]
3.10
load
sterilization batch
sterilization load
product, equipment or materials to be processed together within an operating cycle (3.5)
[SOURCE: ISO 11139:2018, 3.155, modified — the admitted terms "sterilization batch" and "sterilization load" have been added.]
3.11
implant
medical device, or component thereof, that is intended to be introduced into the human body or to replace an epithelial surface or the surface of the eye, by means of surgical intervention and that is intended to remain in place after the procedure
Note 1 to entry: The duration of an implant remaining in the body is dependent on the clinical need.
[SOURCE: ISO 10993-1:2025, 3.21]
3.12
irritation
localized non-specific inflammatory response to single, repeated or continuous application of a substance/material
Note 1 to entry: Skin irritation is a reversible reaction and is mainly characterized by local erythema (redness) and swelling (oedema) of the skin.
[SOURCE: ISO 10993-23:2021, 3.7]
3.13
lowest observed adverse effect level
LOAEL
lowest concentration or amount of an identified constituent found by experiment or observation which causes detectable harm to health (3.9) to the target organism under defined conditions of exposure
[SOURCE: ISO 10993-17:2023, 3.13, modified — Note 1 to entry has been deleted.]
3.14
minimally irritating level
MIL
lowest amount per surface area of an identified constituent that is irritating to the tissue at the contact site as determined by valid experimental or observational evidence
Note 1 to entry: The minimally irritating level is expressed in microgram per centimetre squared (μg/cm2).
[SOURCE: ISO 10993-17:2023, 3.15]
3.15
modifying factor
MF
mathematical product of uncertainty factors (3.26)
[SOURCE: ISO 10993-17:2023, 3.16]
3.16
non-irritating level
NIL
greatest amount per surface area of an identified constituent that does not elicit irritation (3.12) to the tissue at the contact site as determined by valid experimental or observational evidence
Note 1 to entry: The non-irritating level is usually expressed as milligram per centimetre squared per centimetre squared (mg/cm2) or microgram per centimetre squared (μg/cm2).
[SOURCE: ISO 10993-17:2023, 3.17, modified — ‘usually’ and ‘milligram per centimetre squared per centimetre squared (mg/cm2) or’ have been added to Note 1 to entry. ]
3.17
no observed adverse effect level
NOAEL
greatest concentration or amount of an identified constituent found by experiment or observation which causes no detectable harm to health (3.9) to the target organism under defined conditions of exposure
Note 1 to entry: No observed adverse effect level is expressed in microgram per kilogram of body mass per day (μg/kg/d).
[SOURCE: ISO 10993-17:2023, 3.18]
3.18
physiologically based pharmacokinetic modelling
PBPK modelling
system of modelling biological effects taking into account metabolic and pharmacokinetic differences among species of animals
Note 1 to entry: Such data should be utilized whenever available and applicable to medical device anticipated exposure duration.
3.19
residual
quantity of ethylene oxide, ethylene chlorohydrin or ethylene glycol that remains in or on the product after ethylene oxide sterilization
3.20
safety
freedom from unacceptable risk
[SOURCE: ISO 14971:2019, 3.26]
3.21
simulated-use extraction
extraction using a method that simulates clinical use
Note 1 to entry: A simulated-use extraction is performed to estimate the type and amount of substances that are expected to be released from a medical device during its clinical use. A simulated-use extraction is designed to produce an extractables profile that represents the worst-case leachables profile, meaning that all leachables are also extractables and the levels of all individual extractables are at least equal to the level of all individual leachables.
[SOURCE: ISO 10993-18:2020, 3.35]
3.22
tolerable contact level
TCL
estimate of the surface-contact exposure to an identified constituent that is without appreciable irritation (3.12)
Note 1 to entry: Tolerable contact level is expressed in microgram per centimetre squared (μg/cm2) of tissue at the contact site.
[SOURCE: ISO 10993-17:2023, 3.25]
3.23
tolerable exposure
TE
product of the tolerable intake (3.24), the body mass and the concomitant exposure factor (3.4)
Note 1 to entry: Tolerable exposure is normally expressed in milligrams per day to the patient.
3.24
tolerable intake
TI
estimate of the daily exposure of an identified constituent over a specified time period (e.g. acute, subacute, sub-chronic or chronic), on the basis of body mass, that is considered to be without appreciable harm to health (3.9)
Note 1 to entry: Tolerable intake is normally expressed in microgram per kilogram of body mass per day (μg/kg/d). It is derived to establish an allowable limit (3.2) for a medical device constituent.
[SOURCE: ISO 10993-17:2023, 3.26, modified — ‘normally’ has been added and ‘toxicological exposure limit’ has been replaced with ‘an allowable limit (3.2)’ in Note 1 to entry.]
3.25
toxicological risk assessment
determination of whether an exposure dose to a constituent can or cannot elicit appreciable harm to health (3.9)
[SOURCE: ISO 10993-17:2023, 3.29]
3.26
uncertainty factor
UF
numerical value that accounts for uncertainties when extrapolating a point of departure to individuals who can be exposed to a constituent of toxicological concern
EXAMPLE        Extrapolation types include, but are not limited to: intraspecies, interspecies, dose route and study duration.
[SOURCE: ISO 10993-17:2023, 3.31]
30mm
20mm
15mm
15mm
10mm
17mm

Bibliography
[1]
ISO 11135:2014, Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices
[2]
Association for the Advancement of Medical Instrumentation, Good Hospital Practice: Ethylene Oxide Gas — Ventilation Recommendations and Safe Use, Arlington, VA, 1987
[3]
Abdel‑Rahman, M.S. and Kadry, A.M. Studies on the use of uncertainty factors in deriving RfDs, Hum. Ecolog. Risk Assess., 1, pp. 614‑624, 1995
[4]
Abdel‑Rahman, S.Z., El‑Zein, R.A., Ammenheuse, M.M., Yang, Z., Stock, T.H., Morandi, M. and Ward, J.B. Jr. Variability in human sensitivity to 1,3‑butadiene: Influence of the allelic variants of the microsomal epoxide hydrolase gene, Environ. Mol. Mutagen., 41(2), pp. 140‑6
[5]
Abrahams R.H. Recent studies with workers exposed to ethylene oxide, in: Jorkasky J.F., ed., Safe use of ethylene oxide, Proceedings of the Educational Seminar, Washington DC, Health Industries Manufacturers Association, 27‑38, pp. 211‑220, HIMA Report No. 80‑4, 1980
[6]
Adams, C.H., Werely, C.J., Victor, T.C., Hoal, E.G., Rossouw, G., van Helden, P.D. Allele frequencies for glutathione S‑transferase and N‑acetyltransferase 2 differ in African population groups and may be associated with oesophageal cancer or tuberculosis incidence, Clin. Chem. Lab. Med. 41(4), pp. 600‑605, 2003
[7]
Adler, N. Residual ethylene oxide and ethylene glycol in ethylene oxide sterilized pharmaceuticals, J. Pharm. Sci. 1965; 54(5), pp. 735‑742
[8]
Alleva, F. (Cited in Balazs[18], 1976)
[9]
Alomar, A., Camarasa, J.M. and Noguera, J.E.A. Ethylene oxide dermatitis, Contact Dermatitis, 7, pp. 205‑207, 1981
[10]
AMBROSE, A. Toxicological studies of compounds investigated for use as inhibitors of biological processes. II Toxicity of ethylene chlorohydrin. Arch. Ind. Hyg. Occup. Med. 1950; 2:582‑597.
[11]
Anand, V.P., Cogdill, C.P., Klausner, K.A., Lister, L., Barbolt, T., Page, B.F.J., Urbanski, P., Woss Casimir, J., Boyce, J.Reevaluation of ethylene oxide hemolysis and irritation potential, J. Biomed. Mater. Res. 64A, pp. 648‑654, 2003
[12]
Andersen, S. Ethylene oxide toxicity, J. Lab. Clin. Med., 77(2), pp. 346‑356, 1971
[13]
AAMI ST29-1988, Recommended practice for determining residual ethylene oxide in medical devices, Association for the Advancement of Medical Instrumentation, American National Standard. Arlington, VA, AAMI, 1988
[14]
AAMI ST30-1989, Determining residual ethylene chlorohydrin and ethylene glycol in medical devices, Association for the Advancement of Medical Instrumentation, American National Standard. Arlington VA, AAMI, 1989
[15]
ASTM E691-18, Standard practice for conducting an interlaboratory study to determine the precision of a test method
[16]
ATSDR Tp‑90‑16:1990, Toxicological profile for ethylene oxide. Atlanta, GA, US Department of Health and Human Services, Public Health Service
[17]
ATSDR. Toxicological profile for ethylene glycol and propylene glycol. Atlanta, GA, 2010
[18]
Balazs, T. Toxicity of ethylene oxide and chloroethanol, FDA By‑lines No. 3, pp. 150‑155, 1976
[19]
Ball, N.A. Determination of ethylene chlorohydrin and ethylene glycol in aqueous solutions and ethylene oxide in associated plastics, J. Pharm. Sci., 73(9), pp. 1305‑1307, 1984
[20]
Bartels, M.J. Comparison of in vitro metabolism of ethylene glycol in rat and human liver S‑9 homogenate, Midland MI, R&D Report of the Dow Chemical Company, 2001
[21]
Basketter, D.A., Griffiths, H.A., Wang, X.M., Wilhelm, K.P. and McFadden, J. Individual, ethnic and seasonal variability in irritant susceptibility of the skin: the implications for a predictive human patch test, Contact Dermatitis, 35(4), pp. 208‑213, 1996
[22]
Beliles, R.P., Parker, J.C. Risk assessment and oncodynamics of ethylene oxide as related to occupational exposure, Toxicol Ind Health 3(3), pp. 371‑82, 1987
[23]
Bjorge, C., Brunborg, G., Wiger, R., Holme, J.A., Scholz, T., Dybing, E. and Soderlund, E.J. A comparative study of chemically induced DNA damage in isolated human and rat testicular cells, Reprod Toxicol. 10(6), pp. 509‑519, 1996
[24]
Blood, F. Chronic toxicity of ethylene glycol in the rat, Fd. Cosmet. Tox., 3, pp. 229‑234, 1965
[25]
Blood, F., Elliott, G. and Wright, M. Chronic toxicity of ethylene glycol in the monkey, Tox. Appl. Pharm. 4, pp. 489‑491, 1962
[26]
Bommer, J. and Ritz, E. Ethylene oxide as a major cause of anaphylactoid reactions in dialysis (a review). Artif. Organs, 11, pp. 111‑117, 1987
[27]
Bousquet, J. and Michel, F.B. Allergy to formaldehyde and ethylene‑oxide, Clin. Rev. Allergy 9, pp. 357‑370, 1991
[28]
Brobst, K.M. and Han, T. Determination of chlorohydrins in hydroxypropyl starch ethers, J. Assoc. Off. Anal. Chem., 54(5), pp. 1093‑1094, 1971
[29]
Brown, D.J. Determination of ethylene oxide and ethylene chlorohydrin in plastic and rubber surgical equipment sterilized with ethylene oxide, J. Assoc. Off. Anal. Chem., 53(2), pp. 263‑267, 1970
[30]
Bruch, C.W. Industrial Sterilization, eds. Phillips, G.B., Miller, W.S., Duke University Press, Durham, NC, pp. 49‑77, 1973
[31]
BUA, Ethylene oxide, German Chemical Society (GDCh) Advisory Committee on Existing Chemicals of Environmental Relevance (Beratergremium für Umweltrelevante Altstoffe). Stuttgart, Hirzel Verlag (BUA Report 141), 1995
[32]
Buehler, B.A., Rao, V., Finnell, R.H. Biochemical and molecular teratology of fetal hydantoin syndrome, Neurol Clin., 12(4), pp. 741‑748, 1994
[33]
Carpenter, C., Smyth, H. and Pozzani, U. The assay of acute vapor toxicity, and the grading and interpretation of results on 96 chemical compounds, J. Ind. Hyg. Toxicol. 31, pp. 343‑349, 1949 (cited in EPA, 1985)
[34]
Center for Drug Evaluation and Research (CDER), Review Guidance, Validation of Chromatographic Methods, November 1994
[35]
Chesler, S.N., Rebbert, R.E. and Enagonio, D.P. Evaluation of AAMI EO residues recommended practice and a determination of EO kinetics in water, National Bureau of Standards, Department of Commerce, Washington, DC, October 1985
[36]
Choi, S. and Kim, S. Lipopolysaccharide inhibition of rat hepatic microsomal epoxide hydrolase and glutathione S‑transferase gene expression irrespective of nuclear factor‑kappaB activation, Biochem. Pharmacol., 56(11), pp. 1427‑1436, 1988
[37]
Conine, D., Naumann, B. and Hecker, L. Setting health‑based residue limits for contaminants in pharmaceuticals and medical devices, Quality Assurance: Good Practice, Regulation, and Law, 1, pp. 171‑180, 1992
[38]
Courtney, K., Andrews, J. and Grady, M. Teratogenic evaluation of ethylene chlorohydrin (Ech, 2‑chloroethanol) in mice, J. Environ. Sci. Health, B17(4), pp. 381‑391, 1982
[39]
Cyr, W.H., Glaser, Z.R. and Jacobs, M.E. CDRH risk assessment of EO residues on sterilized medical devices, in: Jorkasky, J.; ed. Sterilization in the 1990s (Health Industry Manufacturers Association Report No. HIMA 89‑1). Washington, DC: HIMA, pp. 269‑285, 1989
[40]
Danielson, J.W., Snell, R.P. and Oxborrow, G.S. Detection and quantitation of ethylene oxide, 2‑chloroethanol, and ethylene glycol with capillary gas chromatography, J. Chromatogr., 28, pp. 97‑101, 1990
[41]
Depass, L., Garman, R., Woodside, M., Giddens, W., Maronpot, R. and Weil, C. Chronic toxicity and carcinogenicity studies of ethylene glycol in rats and mice, Fund. Appl. Tox., 7, pp. 547‑565, 1986
[42]
Depass, L., Woodside, M., Maronpot, R. and Weil, C. (1986b) Three‑generation reproduction and dominant lethal mutagenesis studies of ethylene glycol in the rat, Fund. Appl. Tox., 7, pp. 566‑572, 1986
[43]
Dunkelberg, H. Carcinogenicity of ethylene oxide and 1,2‑propylene oxide upon intragastric administration to rats, Br. J. Cancer, 46, pp. 924‑933, 1982
[44]
Edelhauser, H., Antoine, M., Pederson, H., Hiddeman, J. and Harris, R. Intraocular safety evaluation of ethylene oxide and sterilant residues, J. Toxicol. Cut. Ocular Toxicol., 2, pp. 7‑39, 1983
[45]
Ehrenberg, L., Tornqvist, M. The research background for risk assessment of ethylene oxide: aspects of dose, Mutat. Res., 330(1‑2), pp. 41‑54, 1995
[46]
Ethylene Oxide Residues on Sterilized Medical Devices, Environ Corporation, Washington, DC, 1987 (also in: Health Industry Manufacturers Association, HIMA Report 88‑6. Washington, DC, 1988)
[47]
Ettre, LS. and Jones, E. Quantitative analysis with headspace gas chromatography using multiple headspace extraction, Chromatography Newsletter, 12(1), July 1984
[48]
Evans, A.J., Henner, W.D., Eilers, K.M., Montalto, M.A., Wersinger, E.M., Andersen, P.E., Cohen, J.I., Everts, E.C., McWilliams, J.E. and Beer, T.M. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck, 26(1), pp. 63‑70, 2004
[49]
Falzon, M., Milton, A.S., Burke, M.D. Are the decreases in hepatic cytochrome P‑450 and other drug‑metabolising enzymes caused by indomethacin in vivo mediated by intestinal bacterial endotoxins? 16,16‑Dimethylprostaglandin F2 alpha prevents decreases in hepatic drug‑metabolising enzymes due to exogenous endotoxin, Biochem. Pharmacol., 33(8), pp. 1285‑1292, April 15, 1984
[50]
Fennell, T.R., MacNeela, J.P., Morris, R.W., Watson, M., Thompson, C.L., Bell, D.A. Hemoglobin adducts from acrylonitrile and ethylene oxide in cigarette smokers: effects of glutathione S‑transferase T1‑null and M1‑null genotypes, Cancer Epidemiol Biomarkers Prev., 9(7), pp. 705‑712, 2000
[51]
Fennell, T.R. and Brown, C.D. A physiologically based pharmacokinetic model for ethylene oxide in mouse, rat, and human, Toxicol. Appl. Pharmacol., 173(3), pp. 161‑75, 2001
[52]
Fisher, J.W., Dorman, D.C., Medinsky, M.A., Welsch, F., Conolly, R.B. Analysis of respiratory exchange of methanol in the lung of the monkey using a physiological model, Toxicol. Sci., 53(2), pp. 185‑193, 2000
[53]
Fost, U., Tornqvist, M., Leutbecher, M., Granath, F., Hallier, E., Ehrenberg, L. Effects of variation in detoxification rate on dose monitoring through adducts, Hum. Exp. Toxicol., 14(2), pp. 201‑3, 1995
[54]
Fuchs, J., Wullenweber, U., Hengstler, J.G., Bienfait, H.G., Hiltl, G., Oesch, F. Genotoxic risk for humans due to work place exposure to ethylene oxide: remarkable individual differences in susceptibility, Arch Toxicol., 68(6), pp. 343‑8, 1994
[55]
Gaunt, J., Hardy, J., Gangolli, S., Butterworth, K. and Lloyd, A. Bibra, 14, p. 109, 1975 (cited in Rowe and Wolf, 1982 and Environ, 1987)
[56]
Gaylor, D.W. Quantitative Cancer Risk Assessment for Exposure to Ethylene Oxide from Medical Devices, submitted to the CDRH Toxicology Risk Assessment Committee, June 29, 1993
[57]
Glaser, Z.R. Ethylene oxide: Toxicology review and field study results of hospital use, J. Environ. Path. Tox., 2, pp. 173‑208, 1979
[58]
Golberg, L. Hazard Assessment of Ethylene Oxide, CRC Press, Boca Raton, FL, 1986
[59]
Goldblatt, M.W. Brit. J. Ind. Med., 1, p. 213, 1944
[60]
Griffeth, L.K., Rosen, G.M. and Rauchman, E.J. Effects of model traumatic injury on hepatic drug metabolism in the rat. VI. Major detoxification/toxification pathways, Drug Metab. Dispos., 15(6), pp. 749‑59, 1987
[61]
Guess, W. Tissue reactions to 2‑chloroethanol in rabbits, Tox. Appl. Pharm., 16, pp. 382‑390, 1970
[62]
Guidelines for data acquisition and data quality evaluation in environmental chemistry. Anal. Chem., 52(14), 1980
[63]
Hackett P., Brown R., Buschboom R., Clark M., Miller R., Music R. et al. Teratogenic Study of Ethylene Oxide and Propylene Oxide and n‑Butyl Acetate (NIOSH Contract No. 210‑80‑0013), Battelle Pacific Northwest Laboratories, Richland, WA, 1982 (cited in EPA, 1985)
[64]
Hallier, E., Langhof, T., Dannappel, D., Leutbecher, M., Schroder, K., Goergens, H.W., Muller, A. and Bolt, H.M. Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: influence on the induction of sister chromatid exchanges (SCE) in lymphocytes, Arch. Toxicol., 67(3), pp. 173‑178, 1993
[65]
Handlos, V. Determination of gas residuals in ethylene oxide sterilized materials — A literature survey. Archiv. Pharm. Chemi. Sci., 4, pp. 73‑80, 1976
[66]
Handlos, V. The hazards of ethylene oxide sterilization. Arch. Pharm. Chemi. Sci., 7, pp. 939‑949, 1979
[67]
Hanzlik, P., Seidenfeld, M. and Johnson, C. General properties, irritant and toxic actions of ethylene glycol, J. Pharm. Exp. Ther., 41(4) pp. 387‑406, 1931
[68]
Hartman, P.A. and Bowman, P.B. Simple GLC determination of ethylene oxide and its reaction products in drug and formulations, J. Pharm. Sci., 66(6), pp. 789‑792, 1977
[69]
Hassett, C., Lin, J., Carty, C.L., Laurenzana, E.M. and Omiecinski, C.J. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression, Arch. Biochem. Biophys., 337(2), pp. 275‑283, 1997
[70]
Health Industry Manufacturers Association. Guidelines for the Analysis of Ethylene Oxide Residues in Medical Devices (HIMA Document No. 1, Vol. 2). Washington, DC: HIMA, 1980
[71]
Hogstedt, C., Rohlen, O., Berndtsson, B.S., Axelson, O. and Ehrenberg, L. A cohort study of mortality and cancer incidence in ethylene oxide production workers, Br. J. Ind. Med., 36(4), pp. 276‑80, 1979
[72]
Hollingsworth, R., Rowe, V., Oyen, F., McCallister, D. and Spencer, H. Toxicity of ethylene oxide determined on experimental animals. AMA Arch. Ind. Health., 13, pp. 217‑227, 1956
[73]
Hu, J.J., Mohrenweiser, H.W., Bell, D.A., Leadon, S.A. and Miller, M.S. Symposium overview: genetic polymorphisms in DNA repair and cancer risk, Toxicol. Appl. Pharmacol., 185(1), pp. 64‑73, 2002
[74]
Hubaux, A. and Gilbert, V. Decision and detection limits for linear calibration curves,Anal. Chem., 42(8), pp. 849‑855, 1970
[75]
International Agency for Research on Cancer (IARC) (1994) Some industrial chemicals. Ethylene oxide, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 60. IARC, Lyon, pp. 73‑159
[76]
Improved detection and separation of glycols and ethylene oxide residues using GC (Bulletin 789), Supelco, Inc., 1980
[77]
International Conference on Harmonization (ICH). Harmonised Tripartite Guideline; Text on the Validation of Analytical Procedures: Recommended for adoption at step 4 of the ICH process on 27 October 1994
[78]
Jacobson, K., Hackley, E. and Feinsilver, L. The toxicity of inhaled ethylene oxide and propylene oxide vapors, AMA Arch. Ind. Health., 13, pp. 237‑244, 1956
[79]
Japan Association of Disposable Medical Device Industries, Guideline for ethylene oxide sterilization of disposable medical devices (second edition), December 1989
[80]
Johnson, M. Metabolism of chloroethanol in the rat, Biochem. Pharmacol., 16, pp. 185‑199, 1967
[81]
Johnson, M. Detoxication of ethylene chlorohydrin, Fd. Cosmet. Tox., 5, p. 449, 1967
[82]
Jones‑Price C., Kimmel T., Marks T., Ledoux T., Reel J., Fisher P. et al. Teratologic Evaluation of Ethylene Oxide (CAS No. 75‑78‑8) in New Zealand White Rabbits (Final report RB80‑EO, NIEHS Contract No. 1‑ES‑2127). Research Triangle Park, NC, National Institute of Environmental Health Sciences, 1982 (cited in EPA, 1985)
[83]
Jones‑Price, C., Marks, T., Ledoux, T., Reel, J., Fischer, P., Langhoff‑Paschke, L., Marr, M. and Kimmel, C. Teratologic Evaluation of Ethylene Chlorohydrin (CAS No. 107‑07‑3) in New Zealand White Rabbits (PB85‑170959). Research Triangle Park, NC, National Institute of Environmental Health Sciences, 1985a
[84]
Jones‑Price, C., Marks, T., Ledoux, T., Reel, J., Fischer, P., Langhoff‑Paschke, L., Marr, M. and Kimmel, C. Teratologic Evaluation of Ethylene Chlorohydrin (CAS No. 107‑07‑3) in CD‑1 mice (PB85‑172104). Research Triangle Park, NC, National Institute of Environmental Health Sciences, 1985b
[85]
Karel, L., Landing, B. and Harvey, T. The intraperitoneal toxicity of some glycols, glycol ethers, glycol esters and phthalates in mice.Fed. Proceedings, 1947; 6:342
[86]
Kashtock, M. Use of specific retention volumes in evaluation of various types of columns for use in the trace determination of ethylene glycol by gas chromatography, J. Chromatogr., 176, pp. 25‑35, 1979
[87]
Kaye, M.M. and Nevell, T.G. Statistical evaluation of methods using headspace gas chromatography for the determination of ethylene oxide. Analyst., 110, pp. 1067‑1071, 1985
[88]
Kerr, B.M., Rettie, A.E., Eddy, A.C., Loiseau, P., Guyot, M., Wilensky, A.J., Levy, R.H. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation, Clin. Pharmacol. Ther., 46(1), pp. 82‑93, 1989
[89]
Kikuchi, H., Nakamura, A. and Tsuji, K. Gas chromatographic determination with electron capture detection of residual ethylene oxide in intraocular lenses, J. Assoc. Off. Anal. Chem., 71, pp. 1057‑1062, 1988
[90]
Kitteringham, N.R., Davis, C., Howard, N., Pirmohamed, M., Park, B.K. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis‑stilbene oxide, carbamazepine 10, 11‑epoxide and naphthalene, J. Pharmacol. Exp. Ther., 278(3), pp. 1018‑1027
[91]
Knudsen, L.E., Loft, S.H., Autrup, H. Risk assessment: the importance of genetic polymorphisms in man, Mutat. Res., 482(1‑2), pp. 83‑88, 2001
[92]
Lucas,AD;StratmeyerME(2008)Extraction of ethylene oxide residue in medical devicesBiomedical Instrumentation and Technology,42:76-795
[93]
Kroetz, D.L., Kerr, B.M., McFarland, L.V., Loiseau, P., Wilensky, A.J. and Levy, R.H. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects, Clin. Pharmacol. Ther., 53(3), pp. 306‑315, March 1993
[94]
Kulkarni, R.K., Bartak, D., Ousterhout, D.K. and Leonard, F. Determination of residual ethylene oxide in catheters by gas‑liquid chromatography, J. Biomed. Mat. Res., 2, pp. 165‑171, 1968
[95]
Laborde, J. and Kimmel, C. The teratogenicity of ethylene oxide administered intravenously to mice. Tox. Appl. Pharm., 56, pp. 16‑22, 1980
[96]
Lakind, J.S., McKenna, E.A., Hubner, R.P. and Tardiff, R.G. A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol, Crit. Rev. Toxicol., 29(4), pp. 331‑365, 1999
[97]
Lamb, J. IV, Maronpot, R., Gulati, D., Russell, V., Hommel‑Barnes, L. and Sabharwal, P. (1985). Reproductive and developmental toxicity of ethylene glycol in the mouse, Tox. Appl. Pharm. 81, pp. 100‑112, 1985
[98]
Landen, W.O., Thompson, D.W. and Floyd, K.M. Determination of ethylene oxide and ethylene glycol in wet surgical dressings, FDA By‑Lines, No. 2, 1971
[99]
Landin, H.H., Golkar, S.O., Zorcec, V., Tornqvist, M. Biomonitoring of Epicholorhydrin by Hemoglobin Adducts, Anal. Biochem., 240, pp. 1‑6, 1996
[100]
Landin, H.H., Grummt, T., Laurent, C. and Tates, A. Monitoring of occupational exposure to epichlorohydrin by genetic effects and hemoglobin adduct, Mut. Res., 381, pp. 217‑226, 1997
[101]
Latven, A. and Molitor, H. Comparison of the toxic, hypnotic and irritating properties of eight organic solvents, J. Pharm. Exp. Ther., 65, pp. 89‑94, 1939
[102]
Lawrence, W., Turner, J. and Autian, J. Toxicity of ethylene chlorohydrin I: Acute toxicity studies, J. Pharm. Sci., 60(4), pp. 568‑571, 1971
[103]
Lawrence, W., Itoh, K., Turner, J. and Autian, J. Toxicity of ethylene chlorohydrin II: Subchronic toxicity and special tests, J. Pharm. Sci., 60(8), pp. 1163‑1168, 1971
[104]
Lawrence, W., Dillingham, E., Turner, J. and Autian, J. Toxicity profile of chloroacetaldehyde, J. Pharm. Sci., 61(1), pp. 19‑25, 1972
[105]
Lee, HT., Daniel, A. and Walker, C. Conformance test procedures (CTP) for verifying the labelling claims for precision, bias, and interferences in in‑vitro diagnostic devices used for the quantitative measurement of analytes in human body fluids, in Bureau of Medical Devices Biometrics Report 8202, Food and Drug Administration, Silver Spring, MD, April 1982
[106]
Long, G.L. and Winefordner, J.D. Limit of detection — A closer look at the IUPAC definition, Anal. Chem., 55(7), pp. 712A‑724A, 1983
[107]
Lynch, D., Lewis, T., Moorman, W., Sabharwal, P. and Burg, J. Toxic and mutagenic effects of ethylene oxide and propylene oxide on spermatogenic functions in Cynomolgus monkeys, Toxicologist., 3, p. 60, 1982
[108]
Lynch, D., Lewis, T., Moorman, W., Burg, J., Groth, D., Khan, A., Ackerman, L. and Cockerell, B. Carcinogenic and toxicologic effects of inhaled ethylene oxide and propylene oxide in F 344 rats, Tox. Appl. Pharm., 76, pp. 69‑84, 1984
[109]
Lynch D., Lewis T., Moorman W. et al. Effects on monkeys and rats of long‑term inhalation exposure to ethylene oxide: Major findings of the NIOSH study, in In-hospital ethylene sterilization, Current issues in ET0 toxicity and occupational exposure, AAMI Technology Assessment Report No. 8‑84, Association for the Advancement of Medical Instrumentation, Arlington, VA, pp. 7‑10, 1984
[110]
Malanoski, A.J. Analyst performance standards: Determination for and from collaborative studies, J. Assoc. Off. Anal. Chem., 65(6), pp. 1333‑1338, 1982
[111]
Manius, G.J. Determination of ethylene oxide, ethylene chlorohydrin, and ethylene glycol residues in ophthalmic solution at proposed concentration limits, J. Pharm. Sci., 68(12), pp. 1547‑1549, 1979
[112]
Marlowe, D.E., Lao, N.T., Lao, C.S., Eaton, A.R. and Page, B.F.J. Interlaboratory Comparison of Ethylene Oxide Residue Analysis Test Methods (HHS Publication FDA 86‑4204), March 1986
[113]
Marlowe D.E. Summary of results from interlaboratory comparison of ethylene oxide residue analysis test methods, Paper presented at AAMI Conference on In‑hospital EO sterilization, Arlington, VA, November 1983
[114]
Marlowe, D.E., Lao, N.T., Eaton, A.R., Page, B.F.J. and Lao, C.S. An interlaboratory comparison of analytical methods for ethylene oxide, J. Pharm. Sci., 76, pp. 333‑337, 1986
[115]
Maronpot, R., Zelenak, J., Weaver, E. and Smith, N. Teratogenicity study of ethylene glycol in rats, Drug Chem. Tox., 6(6), pp. 579‑594, 1983
[116]
Mason, M., Cate, C. and Baker, J. Toxicology and carcinogenesis of various chemicals used in the preparation of vaccines, Clin. Toxicol., 4(2):185‑204, 1971
[117]
Matsumoto, T., Hardaway, R.M., Pani, K.C., Sater, C.M., Bartak, D.E. and Margetis, P.M. Safe standard of aeration for ethylene oxide sterilized supplies, Arch. Surg., 96, pp. 464‑470, 1968
[118]
McDonald, T., Roberts, M. and Borgmann, A. Ocular toxicity of ethylene chlorohydrin and ethylene glycol in rabbit eyes, Tox. Appl. Pharm., 21, pp. 143‑150, 1972
[119]
McDonald, T., Kasten, K., Hervey, R., Gregg, S., Borgmann, A. and Murcheson, T. Acute ocular toxicity of ethylene oxide, ethylene glycol and ethylene chlorohydrin, Bull. Parent. Drug Assoc., 27(4), pp. 153‑164, 1973
[120]
McDonald, T., Kasten, K., Hervey, R., Gregg, S. and Button, B. Acute ocular toxicity for normal and irritated rabbit eyes and subacute ocular toxicity for ethylene oxide, ethylene chlorohydrin and ethylene glycol, Bull. Parent. Drug Assoc., 31(1), pp. 25‑32, 1977
[121]
McGlynn, K.A., Hunter, K., Levoyer, T., Roush, J., Wise, P., Michielli, R.A., Shen, F.M., Evans, A.A., London, W.T., Buetow, K.H. Susceptibility to a flatoxin B1‑related primary hepatocellular carcinoma in mice and humans, Cancer Res., 63(15), pp. 4594‑4601, 2003
[122]
Melnick, R. (1984). Toxicities of ethylene glycol and ethylene glycol monoethyl ether in Fischer 344/N rats and B6C3F1 mice, Env. Hlth. Perspect., 57, pp. 147‑155, 1984
[123]
Mertes, I., Fleischmann, R., Glatt, H.R. and Oesch, F. Interindividual variations in the activities of cytosolic and microsomal epoxide hydrolase in human liver, Carcinogenesis, 6(2) pp. 219‑223, February 1985
[124]
Millar, M.R., Sharpe, R.M., Weinbauer, G.F., Fraser, H.M., Saunders, P.T. Marmoset spermatogenesis: organizational similarities to the human, Int. J. Androl., 23(5) pp. 266‑77, October 2000
[125]
Mogenhan, J.A., Whitbourne, J.E. and Ernst, R.R. Determination of ethylene oxide in surgical materials by vacuum extraction and gas chromatography, J. Pharm. Sci., 60(2), pp. 222‑224, 1971
[126]
Moore, J.A., Daston, G.P., Faustman, E., Golub, M.S., Hart, W.L., Hughes, C. Jr, Kimmel, C.A., Lamb, J.C., Schwetz, B.A. and Scialli, A.R. An evaluative process for assessing human reproductive and developmental toxicity of agents, Reprod. Toxicol., 9(1), pp. 61‑95, 1995
[127]
Mordenti, J. Man versus beast: pharmacokinetic scaling in mammals, J. Pharm. Sci., 75(11), pp. 1028‑1040, 1986
[128]
Mori, K., Kaido, M., Fujishiro, K., Inoue, N., Koide, O., Hori, H. and Tanaka, I. Dose dependent effects of inhaled ethylene oxide on spermatogenesis in rats, Br. J. Ind. Med., 48(4), pp. 270‑274, April 1991
[129]
Morris, T., Nelson, M. and Calvery, A. Observations on the chronic toxicities of propylene glycol, ethylene glycol, diethylene glycol, ethylene glycol mono‑ethyl‑ether, and diethylene glycol mono‑methyl‑ether, J. Pharm. Exp. Ther., 74, pp. 266‑273, 1942
[130]
Muller, M., Kramer, A., Angerer, J. and Hallier, E. Ethylene oxide‑protein adduct formation in humans: influence of glutathione‑S‑transferase polymorphisms, Int. Arch. Occup. Environ. Health., 71(7), pp. 499‑502, 1998
[131]
Muzeni, R.J. Rapid gas chromatographic determination of ethylene oxide, ethylene chlorohydrin, and ethylene glycol residues in rubber catheters, J. Assoc. Off. Anal. Chem., 68(3), pp. 506‑508, 1985
[132]
Nakamura, A., Kikuchi, H. and Tsuji, K. Determination of ethylene oxide residue in commercially available intraocular lenses by new sensitive method (Electron capture detection/gas chromatography), IOL, 3, pp. 4‑8, 1989
[133]
National Toxicology Program (NTP). Toxicology and Carcinogenicity Studies of 2‑Chloroethanol (Ethylene Chlorohydrin) (CAS. No 107‑07‑3) in F344/N Rats and Swiss CD‑1 Mice (Dermal Studies) (NTP TR275, NIH Publication 86‑2531). Research Triangle Park, NC, NTP, 1985
[134]
National Toxicology Program (NTP). Toxicology and Carcinogenicity Studies of Ethylene Oxide (CAS No. 75‑21‑8) in B6C3F1 Mice (Inhalation Studies) (NTP Technical Report 326, U.S. Department of Health and Human Services, Public Health Services, National Institute of Health). Research Triangle Park, NC, NTP, 1987
[135]
National Toxicology Program (NTP). Toxicology and Carcinogenesis Studies of Ethylene Glycol (CAS No. 107‑21‑1) in B6C3F1 mice (feed studies) (NTP Technical Report 413, U.S. Department of Health and Human Services). Research Triangle Park, NC, NTP, 1993
[136]
National Toxicology Program — Center for the Evaluation of Risks to Human Reproduction Expert Panel, Report on the Reproductive and Developmental Toxicity of Ethylene Glycol. NTP‑CERHR‑EG‑03, 2003
[137]
Neeper‑Bradley T. Developmental Toxicity Evaluation of Ethylene Glycol Administrated by Gavage to CD(R) (Sprague‑Dawley) Rats: Determination of a “No Observable Effect Level” (NOEL), Report 52‑656, Bushy Run Research Center, Union Carbide Corporation, Export, PA (Study sponsored by Ethylene Glycol Panel, Chemical Manufacturers Association. Washington, D.C.), 1990
[138]
Nivard, M.J., Czene, K., Segerback, D. and Vogel, E.W. Mutagenic activity of ethylene oxide and propylene oxide under XPG proficient and deficient conditions in relation to N‑7‑(2‑hydroxyalkyl)guanine levels in Drosophila, Mutat. Res., 529(1‑2), pp. 95‑107, 2003
[139]
Northup, S., Weinckowski, D., Martis, L. and Darby, T. Toxicity caused by acute and subacute intravenous administration of ethylene oxide in the rat, J. Environ. Pathol. Toxicol., 5, pp. 617‑623, 1981
[140]
Oba, T., Tsuji, K., Mizumachi, S., Kikuchi, H., Shintani, H., Iida, K. and Meguro, K. Studies on residual ethylene oxide in medical devices (I) — Gas chromatographic determination of ethylene oxide in plastics. Ikakikai‑gaku, 52(3), pp. 134‑139, 1982
[141]
Ohba, T. Safety of residual ethylene oxide and ethylene oxide concentrations in the working environment of sterilization facilities, in Gaughren, E.; Morrissey, R.; You‑sen, W.; eds., Sterilization of Medical Products Volume IV, Polyscience Publications, Montreal, pp. 172‑177, 1986
[142]
Olsen, A.K., Bjortuft, H., Wiger, R., Holme, J., Seeberg, E., Bjoras, M. and Brunborg, G. Highly efficient base excision repair (BER) in human and rat male germ cells, Nucleic Acids Res. 29(8), pp. 1781‑90, 2001
[143]
Omiecinski, C.J., Aicher, L. and Swenson, L. Developmental expression of human microsomal epoxide hydrolase, J. Pharmacol. Exp. Ther. 269(1), pp. 417‑23, 1994
[144]
Omiecinski, C.J., Hassett, C. and Hosagrahara, V. Epoxide hydrolase‑polymorphism and role in toxicology. Toxicol. Lett., 112‑113, pp. 365‑70, 2000
[145]
Oser, B., Morgareidge, K., Cox, G. and Carson, J. Short‑term toxicity of ethylene chlorohydrin (ECH) in rats, dogs and monkeys, Fd. Cosmet. Tox., 13, pp. 313‑315, 1975
[146]
Pharmaceutical Manufacturers Association. Procedures for setting limits for volatile organic solvents with methylene chloride as an example of the process. Committee on Rational Specifications for Impurities in Bulk Drug Substances — Pharmaceutical Manufacturers Association. In: Pharmacopeial Forum. Washington, DC: PMA, 1989; November‑December, pp. 5748‑5759
[147]
Pharmaceutical Manufacturers Association. Application of the PMA procedure for setting residue limits for organic volatile solvents in pharmaceuticals to ethylene oxide. Prepared by D.L. Conine and the PMA subcommittee of Industrial Toxicologists. Procedures for setting limits for organic volatile solvents with chloroform, 1,4‑dioxane, ethylene oxide, and trichloroethylene as examples of the process. Committee on Rational Specifications for Impurities in Bulk Drug Substances — Pharmaceutical Manufacturers Association. In: Pharmacopeial Forum. Washington, DC: PMA, May‑June:557‑572, 1990
[148]
Pottenger, L.H., Carney, E.W. and Bartels, M.J. Dose‑dependent nonlinear pharmacokinetics of ethylene glycol metabolites in pregnant (GD 10) and nonpregnant Sprague‑Dawley rats following oral administration of ethylene glycol, Toxicol. Sci. 62, pp. 10‑19, 2001
[149]
Price, C., Kimmel, C., Tyl, R. and Marr, M. The developmental toxicity of ethylene glycol in rats and mice, Tox. Appl. Pharm., 81, pp. 113‑127, 1985
[150]
Price, C., Tyl, R., Marr, M. and Kimmel, C. Teratologic evaluation of ethylene glycol (EG) in CD rats and CD‑1 mice, Teratology, 29(2): 52A, 1984
[151]
Ragelis, E.P., Fisher, B.S., Kimeck, B.A. and Johnson, C. Isolation and determination of chlorohydrins in foods fumigated with ethylene oxide or propylene oxide. J. Assoc. Off. Anal. Chem., 51(3), pp. 709‑717, 1968
[152]
Roberts, J. and Seibold, H. Ethylene glycol toxicity in the monkey, Tox. Appl. Pharm. 15, pp. 624‑631, 1969
[153]
Robinson, M., Pond, C., Laurie, R., Bercz, J., Henningsen, G. and Condie, L. Subacute and subchronic toxicity of ethylene glycol administered in drinking water to Sprague‑Dawley rats, Drug Chem. Tox., 13(1), pp. 43‑70, 1990
[154]
Rodricks, J.V. and Brown, S.L. Data requirements for assessment of device risks, J. Am. Coll. Toxicol., 7, pp. 509‑518, 1988
[155]
Romano, S.J. and Renner, J.A. Comparison of analytical methods for residual ethylene oxide analysis, J. Pharm. Sci., 64(8), pp. 1412‑1417, 1975
[156]
Romano, S.J., Renner, J.A. and Leitner, P.M. Gas chromatography determination of residual ethylene oxide by head space analysis, Anal. Chem., 45(14), pp. 2327‑2330, 1973
[157]
Romaguera, C. and Vilaplana, J. Airborne occupational contact dermatitis from ethylene oxide, Contact Dermatitis, 39, p. 85, 1997
[158]
Rossini, A., Rapozo, D.C., Amorim, L.M., Macedo, J.M., Medina, R., Neto, J.F., Gallo, C.V. and Pinto, L.F. Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in a Brazilian population, Genet. Mol. Res., 1(3), pp. 233‑40, 2002
[159]
Rowe, V. and McCollister, S. Alcohols. Chapter Fifty‑Five, in: Clayton, G., Clayton, F., eds. Patty's Industrial Hygiene and Toxicology (3rd ed. Vol. 2C Toxicology), John Wiley & Sons, New York, pp. 4675‑4684, 1982
[160]
Rowe, V. and Wolf, M. Glycols. Alcohols. Chapter Fifty, in: Clayton, G.; Clayton, F.; eds. Patty's Industrial Hygiene and Toxicology (3rd ed. Vol. 2C Toxicology). John Wiley & Sons, New York, pp. 3817‑3832, 1982
[161]
Registry of Toxic Effects of Chemical Substances (RTECS). 1985‑1986, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 87‑114, Rockville, MD, pp. 2361‑2362, 1987
[162]
Registry of Toxic Effects of Chemical Substances (RTECS). National Institute for Occupational Safety and Health, On‑line, Rockville, MD, 2006
[163]
Schroder, K.R., Wiebel, F.A., Reich, S., Dannappel, D., Bolt, H.M. and Hallier, E. Glutathione‑S‑transferase (GST) theta polymorphism influences background SCE rate, Arch. Toxicol., 69(7), pp. 505‑507, 1995
[164]
Schuler, R., Hardin, B., Niemeier, R., Booth, G., Hazelden, K., Piccirillo, V. and Smith, K. Results of testing fifteen glycol ethers in a short‑term in vivo reproductive toxicity assay, Env. Hlth. Perspect. 57, pp. 141‑146, 1984
[165]
Segerback, D., Osterman‑Golkar, S., Molholt, B. and Nilsson, R. In vivo tissue dosimetry as a basis for cross‑species extrapolation in cancer risk assessment of propylene oxide, Regul. Toxicol. Pharmacol. 20(1 Pt 1), pp. 1‑14
[166]
Seilken, R. and Valdez‑Flores, C. Cancer Dose‑Response Modeling and Risk Characterizations Based on Animals Exposed to Ethylene Oxide FINAL REPORT, Submitted to Ethylene Oxide Industry Council, 2000
[167]
Shimizu, H., Ohara, K. and Sawa, M. Sterile anterior segment inflammation presumably due to absorbed ethylene oxide to the implanted intraocular lens, Rinsho Ganka (Japanese J. Clin. Ophthalmol.), 40(11), pp. 1219‑1225, 1986
[168]
Shupack, J.L., Andersen, S.R. and Romano, S.J. Human skin reactions to ethylene oxide. J. Lab. Clin. Med., 98, pp. 723‑729, 1981
[169]
Snellings, W.M., Maronpot, R.R., Zelenak, J.P. et al.Teratology study in Fischer 344 rats exposed to ethylene oxide by inhalation, Toxicol. Appl. Pharmacol., 64, 476‑481, 1982
[170]
Snellings, W., Maronpot, R., Zelenak, J. and Laffoon, C. Teratology study in Fischer 344 rats exposed to ethylene oxide by inhalation, Tox. Appl. Pharm., 64, pp. 476‑481, 1982a
[171]
Snellings, W., Zelenak, J. and Weil, C. Effects on reproduction in Fischer rats exposed to ethylene oxide by inhalation for one generation, Tox. Appl. Pharm., 63, pp. 382‑388, 1982b
[172]
Snellings, W., Weil, C. and Maronpot, R. A subchronic inhalation study on the toxicologic potential of ethylene oxide in B6C3F1 mice, Tox. Appl. Pharm., 76, pp. 510‑518, 1984a
[173]
Snellings, W., Weil, C. and Maronpot, R. A two‑year inhalation study of the carcinogenic potential of ethylene oxide in Fischer 344 rats, Tox. Appl. Pharm., 75, pp. 105‑117, 1984b
[174]
Snyder, L.R. A rapid approach to selecting the best experimental conditions for high‑speed liquid column chromatography — Part 1 — Estimating initial sample resolution and the final resolution required by a given problem, J. Chromatogr. Sci.; 10, pp. 201‑212, 1972
[175]
Spitz, H.D. and Weinberger, J. Determination of ethylene oxide, ethylene chlorohydrin and ethylene glycol by gas chromatography, J. Pharm. Sci., 60(2), pp. 271‑274, 1971
[176]
Stayner, L., Steenland, K., Greife, A., Hornung, R., Hayes, R.B., Nowlin, S., Morawetz, J., Ringenburg, V., Elliot, L. and Halperin, W. Exposure‑response analysis of cancer mortality in a cohort of workers exposed to ethylene oxide, Am. J. Epidemiol., 138(10), pp. 787‑98, 1993
[177]
Steenland, K., Stayner, L., Greife, A. et al.A cohort mortality study of workers exposed to ethylene oxide, N. Engl. J. Med., 324, pp. 402‑407, 1991
[178]
Steenland, K., Stayner, L. and Deddens, J. Mortality analysis in a cohort of 18235 ethylene oxide exposed workers: follow up extended from 1987 to 1998, Occup. Environ. Med., 61, pp. 2‑7, 2004
[179]
Tanaka, S., Nakaura, S., Kawashima, K., Kasuya, Y. and Omori, Y. Studies on the hemolytic activity and dermal irritability of ethylene oxide and its reaction products. Jap. J. Med. Instrum. 52(1), pp. 21‑28, 1982
[180]
Taylor, J.S. Dermatologic hazards from ethylene oxide, Cutis, 19, pp. 189‑192, 1977
[181]
Teta, M.J., Sielken, R.L. jr.m and Valdez‑Flores, C. Ethylene oxide cancer risk assessment based on epidemiological data: application of revised regulatory guidelines, Risk Anal. 19(6), pp. 1135‑55, 1999
[182]
Thier, R., Lewalter, J., Kempkes, M., Selinski, S., Bruning, T. and Bolt, H.M. Haemoglobin adducts of acrylonitrile and ethylene oxide in acrylonitrile workers, dependent on polymorphisms of the glutathione transferases GSTT1 and GSTM1, Arch. Toxicol., 73(4‑5), pp. 197‑202, 1999
[183]
Thier, R., Bruning, T., Roos, P.H., Rihs, H.P., Golka, K., Ko, Y. and Bolt, H.M. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes, Int. J. Hyg. Environ. Health., 206(3), pp. 149‑71, 2003
[184]
Thier, R., Balkenhol, H., Lewalter, J., Selinski, S., Dommermuth, A. and Bolt, H.M. Influence of polymorphisms of the human glutathione transferases and cytochrome P450 2E1 enzyme on the metabolism and toxicity of ethylene oxide and acrylonitrile, Mutat. Res., 482(1‑2), pp. 41‑46, 2001
[185]
Tyl R. Developmental Toxicity Evaluation of Ethylene Glycol Administrated by Gavage to DC(R)‑1 Mice: Determination of a “No‑Observable‑Effect Level” (NOEL), Report 51‑591, Bushy Run Research Center. Union Carbide Corporation, Export, PA. (Study sponsored by Ethylene Glycol Panel.) Washington, DC, Chemical Manufacturers Association, 1988
[186]
Tyler T.R., McKelvey J.A. Dose dependent disposition of 14C labelled ethylene oxide in rats, Export, PA, Bushy Run Research Center (TSCATS/017061; EPA/OTS Document No. 878212056),1982
[187]
US Environmental Protection Agency. (1985) Health Assessment Document for Ethylene Oxide (EPA 600/8‑84‑009F). Research Triangle Park, NC, EPA, 1985. https://iris.epa.gov/Document/&deid=41115
[188]
US Environmental Protection Agency. (1996) Guidelines for Reproductive Toxicity Risk Assessment EPA/630/R‑96/009. https://www.epa.gov/ncea/raf/pdfs/repro51.pdf
[189]
U.S. Food and Drug Administration. EO, ECH & EG, Proposed maximum residue limits and maximum levels of exposure (HEW/FDA), Federal Register. Washington, DC, June 23, 1978; 43(122)
[190]
Chromatography U.S.P. (section 621) in: United States Pharmacopeia 29th Edition, United States Pharmacopeial Convention 2006
[191]
USP Validation of Compendial Methods (section 1225) in: United States Pharmacopeia 29th Edition, United States Pharmacopeial Convention 2006
[192]
Vogel, E.W. and Natarajan, A.T. DNA damage and repair in somatic and germ cells in vivo, Mutat. Res., 330(1‑2), pp. 183‑208, 1995
[193]
Warren, B. The determination of residual ethylene oxide and halogenated hydrocarbon propellants in sterilized plastics, J. Pharm. Pharmacol., 23(suppl.), pp. 170S‑175S, 1971
[194]
Weil, C. Statistics vs. safety factors and scientific judgement in the evaluation of safety for man, Tox. Appl. Pharm., 21, pp. 454‑463, 1972
[195]
Weinbauer, G.F., Aslam, H., Krishnamurthy, H., Brinkworth, M.H., Einspanier, A. and Hodges, J.K. Quantitative analysis of spermatogenesis and apoptosis in the common marmoset (Callithrix jacchus) reveals high rates of spermatogonial turnover and high spermatogenic efficiency, Biol. Reprod. 64(1), pp. 120‑126, 2001
[196]
Weinberger, J. GLC Determination of ethylene chlorohydrin following co‑sweep extraction, J. Pharm. Sci., 60(4), pp. 545‑547, 1971
[197]
Wernerman, J., Luo, J.L. and Hammarqvist, F. Glutathione status in critically‑ill patients: possibility of modulation by antioxidants, Proc. Nutr. Soc., 58(3), pp. 677‑680, 1999
[198]
Wesley, F., Rourke, B. and Darbishire, O. The formation of persistent toxic chlorohydrins in foodstuffs by fumigating with ethylene oxide and propylene oxide, J. Food Sci., 30, pp. 1037‑1042, 1965
[199]
Whitbourne, J.E., Mogenhan, J.A. and Ernst, R.R. Determination of 2‑chloroethanol in surgical materials by extraction and gas chromatography, J. Pharm. Sci., 58(3), pp. 1024‑1025, August 1969
[200]
White, J.D. and Bradley, T.J. Residual ethylene oxide in methyl methacrylate polymer powders by GLC, J. Pharm. Sci., 62(10), pp. 1623‑1637, 1973
[201]
World Health Organization (WHO). Ethylene Oxide. Concise International Chemical Assessment Document 54, WHO, Geneva, 2003. https://iris.who.int/bitstream/handle/10665/42639/9241530545.pdf?sequence=1
[202]
Wiencke, J.K., Premble, S., Kettere, B. and Kelsey, K.T. Gene deletion of Glutathione‑S‑transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis, Cancer Epidemiol. Biomarkers Prev., 4(3), pp. 253‑259, 1995
[203]
Woodard G., Woodard M. Toxicity of residuals from ethylene oxide gas sterilization. Proceedings of the Health Industry Association Technical Symposium, Washington, DC, pp. 140‑161, 1971
[204]
Yin, L., Liu, C., Shih, L. and Po, K. A study of the teratogenic action of ethylene glycol in rats, Zhonghua Yugangyixue Zazhi, 20(5), 289‑290, 1986
[205]
Yong, L.C., Schulte, P.A., Wiencke, J.K., Boeniger, M.F., Connally, L.B., Walker, J.T., Whelan, E.A. and Ward, E.M. Hemoglobin adducts and sister chromatid exchanges in hospital workers exposed to ethylene oxide: effects of glutathione S‑transferase T1 and M1 genotypes, Cancer Epidemiol. Biomarkers Prev., 10(5), pp. 539‑550, 2001
[206]
Zagar, L.A. Determination of residual ethylene oxide in methyl methacrylate polymer powders by GLC, J. Pharm. Sci., 61(11), pp. 1801‑1803, 1972
[207]
Zheng, W., Wen, W.Q., Gustafson, D.R., Gross, M., Cerhan, J.R. and Folsom, A.R. GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk, Breast Cancer Res. Treat., 74(1), p. 9, 2002
[208]
ICH Q2R1 Validation of Analytical Procedures: Text and Methodology – Nov 2005
[209]
Validation of analytical procedures: Text and methodology Q2 (R1), ICH Harmonised Tripartite Guideline, November 2005
[210]
Harmonized Guidelines for Single Laboratory Validation Methods of Analysis (IUPAC Technical Report). Pure Appl. Chem., Vol. 74, No. 5, pp. 835.855, 2002
[211]
AOAC Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals (December 12, 2002)
[212]
Guidance for industry - Analytical Procedures and Methods Validation for Drugs and Biologics, US. Department of Health and Human Services, FDA, July 2015
[213]
Harmonisation of strategies for the validation of quantitative analytical procedures A SFSTP proposal Part I. J. Pharm. Biomed. Anal. 2004, 36 pp. 579–586
[214]
Eurachem, The Fitness for Purpose of Analytical Methods, A Laboratory Guide to Method Validation and Related Topics. Second Edition, 2014
[215]
Gimeno, Auguste, Handlos, Nielsen, Schmidt, Lassu, Vogel, Fischer, Brenier, Duperray, Identification and quantification of ethylene oxide in sterilized medical devices using multiple headspace GC/MS measurement, Journal of Pharmaceutical and Biomedical Analysis, 158 (2018) 119–127
[216]
AD Lucas, C Forrey, D Saylor, K Vorvolakos. Solvent or thermal extraction of ethylene oxide from polymeric materials: Medical device considerations, JBMR 2018:106B, 2455-2463
[217]
Lucas, AD; Merritt, K; Hitchins, V; Woods, T.; McNamee, S; Lyle, DB; Brown, SA. (2003) Residual Ethylene Oxide in Medical Devices and Device Material J. of Biomed. Mat. Res. Appl. Biomat. 66B:548-552
[218]
Handlos V. Kinetics of the aeration of ethylene-oxide sterilized plastics. Biomaterials. 1980 Jul 1;1(3):149–57
[219]
Vink P, Pleijsier K. Aeration of ethylene oxide-sterilized polymers. Biomaterials. 1986 May 1;7(3):225–30
[220]
Grunow, W., Altmann, HJ. Toxicokinetics of chloroethanol in the rat after single oral administration,Arch. Toxicol.,49(3-4), pp. 275-284, 1982
[221]
U.S. Environmental Protection Agency. (2012) Provisional Peer-Reviewed Toxicity Values for 2-Chloroethanol (CASRN 107-07-3) EPA/690/R‑12/007F. https://cfpub.epa.gov/ncea/pprtv/documents/Chloroethanol2.pdf
[222]
ISO 10993-4:2017, Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood
[223]
ISO 10993-17:2023, Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents
[224]
ISO 10993-18:2020, Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process
[225]
ISO 11139:2018, Sterilization of health care products — Vocabulary of terms used in sterilization and related equipment and process standards
[226]
ISO 11979-5:2020, Ophthalmic implants — Intraocular lenses — Part 5: Biocompatibility
[227]
ISO 14971:2019, Medical devices — Application of risk management to medical devices
[228]
Woodman (2005) Ethylene Oxide Residuals Detected on Medical Devices after Processing in the EO Gas 4 Three-hour Exposure Cycle. Andersen Scientific, Inc. Protocol No.: ANSCI081205S4. https://www.sterility.com/wp-content/uploads/PN0000_-092821-EO4-Residuals.pdf
[229]
“Metal and glass do not absorb ethylene oxide, but may retain pockets of gas in semi-closed cavities.” GUIDANCE NOTE FOR THE SAFE USE OF ETHYLENE OXIDE IN STERILISATION /FUMIGATION PROCESSES [NOHSC:3016(1992)], Section 1.6, p.48. https://www.safeworkaustralia.gov.au/system/files/documents/1702/guidancenote_safeuseofethyleneoxideinsterilisationfumigationprocesses_nohsc3016-1992_pdf.pdf
[230]
American Chemistry Council (ACC). Ethylene Oxide Product Stewardship Guidance Manual. Feb 2 2023, p.15. https://www.americanchemistry.com/industry-groups/ ethylene-oxide/resources/ ethylene-oxide-product-stewardship-manual-2023
[231]
Agency for Toxic Substances and Disease Registry (ATSDR). 2022. Toxicological Profile for Ethylene Oxide. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service
[232]
International Agency for Research on Cancer (IARC) (2012) Chemical agents and related occupations, Ethylene oxide. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100F: A Review of Human Carcinogens. IARC, Lyon, pp 379–400
[233]
Kirman & Hays. Derivation of endogenous equivalent values to support risk assessment and risk management decisions for an endogenous carcinogen: Ethylene oxide, Regulatory Toxicology and Pharmacology, 91, 2017, 165-172. https://doi.org/10.1016/j.yrtph.2017.10.032
[234]
Lynch et al. Systematic review of the scientific evidence on ethylene oxide as a human carcinogen. Chemico-Biological Interactions, Volume 364, 2022, 110031. https://doi.org/10.1016/j.cbi.2022.110031
[235]
Marsh G.M., et al. Ethylene oxide and risk of lympho-hematopoietic cancer and breast cancer: a systematic literature review and meta-analysis. (2019) International Archives of Occupational and Environmental Health, 92 (7), pp. 919 – 939. DOI: 10.1007/s00420-019-01438-z
[236]
Mikoczy et al. (2011) Cancer incidence and mortality in Swedish sterilant workers exposed to ethylene oxide: updated cohort study findings 1972-2006. Int J Environ Res Public Health 8:2009–2019. https://doi.org/10.3390/ijerph8062009
[237]
National Toxicology Program (NTP). 2021. Report on Carcinogens, Fifteenth Edition. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service.3https://doi.org/10.22427/NTP-OTHER-1003
[238]
Scientific Committee on Occupational Exposure Limits (SCOEL). Recommendation from the Scientific Committee on Occupational Exposure Limits for ethylene oxide. European Commission. SCOEL/SUM/160. June 2012
[239]
Sheehan et al. Ethylene Oxide Exposure in U.S. Populations Residing Near Sterilization and Other Industrial Facilities: Context Based on Endogenous and Total Equivalent Concentration Exposures. Int. J. Environ. Res. Public Health 2021, 18, 607. https://doi.org/10.3390/ijerph18020607
[240]
Texas Commission on Environmental Quality (TCEQ). Ethylene Oxide Carcinogenic Dose-Response Assessment. Development Support Document. Texas Commission on Environmental Quality. Final, May 15, 2020
[241]
Valdez-Flores et al. Quantitative cancer risk assessment based on NIOSH and UCC epidemiological data for workers exposed to ethylene oxide, Regulatory Toxicology and Pharmacology, Volume 56, Issue 3, 2010, Pages 312-320, ISSN 0273-2300. https://doi.org/10.1016/j.yrtph.2009.10.001
[242]
Valdez-Flores, C., Sielken, R.L. & Jane Teta, M. Quantitative cancer risk assessment for ethylene oxide inhalation in occupational settings. Arch Toxicol 85, 1189–1193 (2011). https://doi.org/10.1007/s00204-011-0669-2
[243]
Vincent et al. Ethylene Oxide: Cancer Evidence Integration and Dose–Response Implications (2019) Dose-Response, 17 (4) DOI: 10.1177/1559325819888317
[244]
US Environmental Protection Agency. (2016) Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide (CASRN 75-21-8). EPA/635/R-16/350Fa. https://iris.epa.gov/static/pdfs/1025tr.pdf
[245]
Fryar C.D. et al. Anthropometric reference data for children and adults, Vital and health statistics. Series 3, Analytical and epidemiological studies; no. 46 : United States, 2015-2018; Published Date : January 2021. https://stacks.cdc.gov/view/cdc/100478
[246]
Koch-Institut R. (2017) Reference percentiles for anthropometric measures and blood pressure based on the German Health Interview and Examination Survey for Children and Adolesce [KiGGS - Kinder- und Jugendgesundheitsstudie, 2011]. Version: 1. RKI-Bib1 (Robert Koch-Institut). https://doi.org/10.17886/RKI-GBE-2016-032
[247]
The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects, Clin Exp Pediatr. 2018;61(5):135-149. Published online May 28, 2018. https://doi.org/10.3345/kjp.2018.61.5.135
[248]
NIST Special Publication 811:2008, Guide for the Use of the International System of Units (SI)
30mm
20mm
15mm
15mm
10mm
17mm
30mm
20mm
15mm
15mm
10mm
17mm
ICS 11.100.20
Price based on 122 pages
iso.org